Publications by authors named "Andre Goy"

100Publications

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Sci Immunol 2020 06 5;5(48). Epub 2020 Jun 5.

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD; Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR; Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD; John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ; Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO; Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO; US Acute Care Solutions, Canton, OH; Department of Medicine, St. Peter's Hospital and US Oncology, Albany, NY; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD; Acerta Pharma, South San Francisco, CA; Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA AstraZeneca, One MedImmune Way, Gaithersburg, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciimmunol.abd0110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274761PMC
June 2020

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

N Engl J Med 2020 04;382(14):1331-1342

From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) - both in Florida; Dana-Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen School of Medicine at UCLA, Los Angeles (J.M.T.), Stanford University School of Medicine, Stanford (D.B.M.), and Kite, a Gilead company, Santa Monica (W.P., L.Z., J.M.R., R.K.J., A.V.R.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Colorado Blood Cancer Institute, Denver (P.A.M.); Swedish Cancer Institute, Seattle (J.M.P.); the Academic Medical Center, University of Amsterdam, Amsterdam, for the Lunenburg Lymphoma Phase I/II Consortium (M.-J.K.); Centre Hospitalier Universitaire (CHU) Bordeaux, Service d'Hematologie et Therapie Cellulaire, Bordeaux (N.M.), and CHU Rennes, INSERM French Blood Establishment, Rennes (R.H.) - both in France; Fox Chase Cancer Center, Philadelphia (H.F.); Universitätsklinikum Würzburg, Würzburg, Germany (M.S.T.); and the University of Rochester Medical Center, Rochester, NY (P.M.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914347DOI Listing
April 2020

Contemporary management of nodal and primary splenic marginal zone lymphoma.

Expert Rev Hematol 2019 12 12;12(12):1011-1022. Epub 2019 Nov 12.

Lymphoma Division, John Theurer Cancer Center, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1681962DOI Listing
December 2019

Game Changers in Treatment of Hematologic Malignancies.

Authors:
Andre Goy

Oncology (Williston Park) 2019 Sep 20;33(9). Epub 2019 Sep 20.

View Article

Download full-text PDF

Source
September 2019

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Leuk Lymphoma 2019 09 8;60(9):2255-2263. Epub 2019 Mar 8.

Department of Hematology and Oncology, Winship Cancer Institute, School of Medicine, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1574006DOI Listing
September 2019

To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

J Oncol Pharm Pract 2019 06 20;25(4):1027-1030. Epub 2019 Feb 20.

6 Washington University of Medicine, Siteman Cancer Center, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219831435DOI Listing
June 2019

Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer.

Breast 2018 Jun 12;39:101-109. Epub 2018 Apr 12.

The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ 07601, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776183006
Publisher Site
http://dx.doi.org/10.1016/j.breast.2018.03.015DOI Listing
June 2018

Reply to H. Tilly et al.

Authors:
Andre Goy

J Clin Oncol 2018 03 25;36(9):923-925. Epub 2018 Jan 25.

Andre Goy, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.8754
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.8754DOI Listing
March 2018

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med 2017 12 10;377(26):2531-2544. Epub 2017 Dec 10.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine, Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485PMC
December 2017

Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials.

Authors:
Andre Goy

J Clin Oncol 2017 11 19;35(31):3519-3522. Epub 2017 Sep 19.

Andre Goy, Hackensack University Medical Center, Hackensack, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7360DOI Listing
November 2017

Treatment of Peripheral T-Cell Lymphoma in Community Settings.

Clin Lymphoma Myeloma Leuk 2017 06 10;17(6):354-361. Epub 2017 May 10.

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA Inc, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.05.001DOI Listing
June 2017

Targeting indolent non-Hodgkin lymphoma.

Expert Rev Hematol 2017 Apr 15;10(4):299-313. Epub 2017 Mar 15.

a Lymphoma Division , John Theurer Cancer Center , Hackensack , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1303374DOI Listing
April 2017

Protein calorie malnutrition, nutritional intervention and personalized cancer care.

Oncotarget 2017 Apr;8(14):24009-24030

The Genomics and Biomarkers Program, JT Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410360PMC
April 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

Point: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma: Where It Fits in the New Paradigm.

Authors:
Andre Goy

Oncology (Williston Park) 2016 12;30(12):1055-8, 1060

View Article

Download full-text PDF

Source
December 2016

Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?

Authors:
Andre Goy

Hematol Oncol Clin North Am 2016 Dec;30(6):1345-1370

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588163010
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2016.07.014DOI Listing
December 2016

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Oncotarget 2016 07;7(30):48692-48731

The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217048PMC
July 2016

The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.

J Ovarian Res 2016 Mar 31;9:20. Epub 2016 Mar 31.

The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ, 07601, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-016-0228-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815131PMC
March 2016

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

J Clin Oncol 2016 Apr 25;34(10):1112-21. Epub 2016 Jan 25.

Jennifer N. Brudno, Robert P.T. Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Steven A. Feldman, Alexander T. Iwamoto, Brenna G. Hansen, Bazetta Blacklock-Schuver, Frances T. Hakim, Steven A. Rosenberg, Ronald E. Gress, and James N. Kochenderfer, National Cancer Institute; Roger Kurlander and Irina Maric, National Institutes of Health, Bethesda; Jennifer S. Wilder, Frederick National Laboratory for Cancer Research, Frederick, MD; and Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.5929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872017PMC
April 2016

Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Oncotarget 2015 Oct;6(30):28693-715

Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.4981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745686PMC
October 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.

Clin Cancer Res 2015 Sep 9;21(17):3853-61. Epub 2015 Jun 9.

John Theurer Cancer Center at HUMC, Hackensack, New Jersey.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-0488DOI Listing
September 2015

Lenalidomide for mantle cell lymphoma.

Expert Rev Hematol 2015 Jun;8(3):257-64

John Theurer Cancer Center at Hackensack University Medical Center, Department of Lymphoma, Bone and Marrow Transplantation Program, 92 Second Street, Hackensack, NJ 07601, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/17474086.2015.10
Publisher Site
http://dx.doi.org/10.1586/17474086.2015.1035706DOI Listing
June 2015

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.

Br J Haematol 2015 Aug 24;170(4):504-14. Epub 2015 Apr 24.

Center for Chronic Lymphocytic Leukemia and Lymphoma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.13463
Publisher Site
http://dx.doi.org/10.1111/bjh.13463DOI Listing
August 2015

Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine.

J Clin Bioinforma 2015 26;5. Epub 2015 Mar 26.

Genomics and Biomarkers Program, Hackensack University Medical Center, Hackensack, NJ 07601 USA ; John Theurer Cancer Center, Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13336-015-0019-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381462PMC
April 2015

A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Clin Lymphoma Myeloma Leuk 2015 Jul 5;15(7):392-7. Epub 2015 Mar 5.

Department of Medicine, University of Washington School of Medicine, and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650150006
Publisher Site
http://dx.doi.org/10.1016/j.clml.2015.02.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484300PMC
July 2015

Mantle cell lymphoma: state of the art.

Clin Adv Hematol Oncol 2015 Jan;13(1):44-55

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.

View Article

Download full-text PDF

Source
January 2015

Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.

J Ovarian Res 2014 Dec 5;7:109. Epub 2014 Dec 5.

The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ, 07601, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-014-0109-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271347PMC
December 2014

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

J Clin Oncol 2015 Feb 25;33(6):540-9. Epub 2014 Aug 25.

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.2025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322257PMC
February 2015

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.

Leuk Lymphoma 2014 Dec 6;55(12):2761-8. Epub 2014 May 6.

John Theurer Cancer Center, Hackensack University Medical Center , Hackensack, NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.907891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349217PMC
December 2014

Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.

Leuk Lymphoma 2014 Dec 22;55(12):2932-4. Epub 2014 Apr 22.

John Theurer Cancer Center, Hackensack University Medical Center , Hackensack, NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.900760DOI Listing
December 2014

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

J Clin Oncol 2013 Oct 3;31(29):3688-95. Epub 2013 Sep 3.

Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack; Lei Zhang, Sherri Cicero, and Tommy Fu, Celgene, Summit, NJ; Rajni Sinha, Emory University Winship Cancer Institute, Atlanta, GA; Michael E. Williams, University of Virginia Health System, Charlottesville, VA; Sevgi Kalayoglu Besisik, Istanbul University Faculty of Medicine, Istanbul, Turkey; Johannes Drach, Medical University of Vienna, Vienna, Austria; Radhakrishnan Ramchandren, Karmanos Cancer Institute, Detroit, MI; and Thomas E. Witzig, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879693PMC
October 2013

Mantle cell lymphoma: the changing landscape.

Authors:
Andre Goy

Clin Adv Hematol Oncol 2013 Sep;11 Suppl 14(9):11-5

Hackensack University Medical Center, Hackensack, NJ.

View Article

Download full-text PDF

Source
September 2013

Update in the management of mantle cell lymphoma.

Authors:
Andre Goy

Clin Adv Hematol Oncol 2013 May;11(5):297-9

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
May 2013

Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.

J Oncol 2013 30;2013:368751. Epub 2013 May 30.

The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/368751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683471PMC
July 2013

Osteomyelitis of the patella caused by Legionella anisa.

J Clin Microbiol 2013 Aug 12;51(8):2791-3. Epub 2013 Jun 12.

Microbiology and Molecular Pathology, Department of Pathology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JCM.03190-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719613PMC
August 2013

The role of the ubiquitin proteasome system in lymphoma.

Crit Rev Oncol Hematol 2013 Sep 27;87(3):306-22. Epub 2013 Mar 27.

John Theurer Cancer Center, Hackensack University Medical Center, NJ 07601, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.02.005DOI Listing
September 2013

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.

Leuk Lymphoma 2013 Oct 8;54(10):2185-9. Epub 2013 Mar 8.

Florida Center for Cellular Therapy, Florida Hospital Cancer Institute , Orlando, FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.772294DOI Listing
October 2013

Early detection biomarkers for ovarian cancer.

J Oncol 2012 23;2012:709049. Epub 2012 Dec 23.

The Genomics and Biomarker Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/709049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540796PMC
January 2013

Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Oncologist 2012 7;17(5):694-707. Epub 2012 May 7.

Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-0341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360909PMC
January 2013